[68Ga]FAPI-46 PET/CT 肿瘤表征可改善胰腺癌患者治疗选择:一项前瞻性临床试验的中期分析
这项前瞻性临床试验中期分析纳入 30 例拟行手术切除的疑似胰腺癌患者,评估[68Ga]FAPI-46 PET/CT 的诊断准确性。组织病理学显示 20 例恶性、10 例良性;恶性病变摄取显著高于良性(P < 0.001),SUVmax 最佳 cutoff 为 10.2,全队列灵敏度 95%、特异度 80%。作者结论认为该显像可准确鉴别标准影像难以定性的胰腺良恶性病变,并提出其可作为补充工具。
要点
- [68Ga]FAPI-46 PET/CT 在疑似胰腺癌患者中,恶性病变摄取显著高于良性病变(P < 0.001)。
- SUVmax 最佳 cutoff 为 10.2,全队列灵敏度 95%、特异度 80%。
- 在影像学定性困难的亚组中,SUVmax 10.2 的诊断准确性为 100%。
核心结论
- 作者结论认为[68Ga]FAPI-46 PET/CT 能准确鉴别标准影像判定为定性困难的胰腺良恶性病变。
- 作者提出[68Ga]FAPI-46 PET/CT 不仅可作为临床补充手段,当标准影像无法得出结论时也可能成为必要工具。
研究设计与样本
- 这是一项前瞻性临床试验的中期分析,对 30 例拟行手术切除的疑似胰腺癌患者行[68Ga]FAPI-46 PET/CT 显像。
- 勾画目标病灶并测定 SUVmax 与 SUVmean,与标准影像结果比较,以术后组织病理学为参考标准。
- 对全队列及术前临床影像学定性困难的 11 例亚组计算受试者工作特征曲线,并确定统计效能所需样本量。
主要发现
- 术后组织病理学检查显示 20 例为恶性、10 例为良性病变。
- 恶性肿瘤的[68Ga]FAPI-46 摄取较良性病变显著升高(P < 0.001)。
- 受试者工作特征分析确定了区分胰腺良恶性肿瘤的 SUV 最佳 cutoff,SUVmax 最佳 cutoff 为 10.2。
- SUVmax cutoff 10.2 在全队列的灵敏度为 95%、特异度为 80%,在仅考虑影像学定性困难亚组时诊断准确性为 100%。
- 为达到足够统计效能,需要 38 例定性困难的观察。
关键数值与推荐
- SUVmax 最佳 cutoff 为 10.2,全队列灵敏度 95%、特异度 80%。
- 在影像学定性困难亚组中,SUVmax 10.2 的诊断准确性为 100%。
- 为达到足够统计效能,需要 38 例定性困难的观察。
临床怎么用
- 作者提出[68Ga]FAPI-46 PET/CT 不仅可作为临床补充手段,当标准影像无法得出结论时也可能成为必要工具。
- 该试验将继续招募共 120 例患者,以达到足够统计效能所需的 38 例定性困难观察。
局限性
- 本文为前瞻性临床试验的中期分析,样本量为 30 例,其中影像学定性困难亚组为 11 例。
- 作者指出该试验将继续招募共 120 例患者,以达到足够统计效能所需的 38 例定性困难观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Correct and timely diagnosis of pancreatic cancer (PC) is essential for treatment selection but is still clinically challenging. Standard-of-care imaging methods can sometimes not differentiate malignancies from inflammatory lesions or detect malignant transformation in premalignant lesions. This interim analysis of a prospective clinical trial aimed to evaluate the diagnostic accuracy of [68Ga]fibroblast activation protein inhibitor (FAPI)-46 PET/CT for PC and determine the sample size needed to demonstrate whether this imaging technique improves the characterization of equivocal lesions detected by standard-of-care imaging methods. Methods: [68Ga]FAPI-46 PET/CT imaging was performed on 30 patients scheduled for surgical resection of suspected PC. Target lesions were delineated, SUVmax and SUVmean were determined, and the results were compared with those of standard-of-care imaging. Receiver operating characteristics were calculated for the whole cohort and a subcohort of 11 patients with an equivocal clinical imaging work-up preoperatively. Postoperative histopathologic findings served as a reference standard, and the statistical power was determined. Results: Histopathologic examination revealed malignancy in 20 patients and benign lesions in 10 patients. Significantly elevated [68Ga]FAPI-46 uptake was observed in malignant tumors compared with benign lesions (P < 0.001). Receiver-operating-characteristic analyses established optimal cutoffs for both SUVs for differentiation of malignant from nonmalignant pancreatic tumors. The optimal SUVmax cutoff was 10.2 and showed 95% sensitivity and 80% specificity for the whole cohort, as well as 100% diagnostic accuracy when considering the subcohort with equivocal imaging work-up only. For sufficient statistical power, 38 equivocal observations are needed. Conclusion: We conclude that [68Ga]FAPI-46 PET/CT can accurately differentiate malignant from benign pancreatic lesions deemed equivocal by standard-of-care imaging. This trial will therefore continue to recruit a total of 120 patients to reach those 38 equivocal observations needed for sufficient statistical power. On the basis of our findings, we propose that [68Ga]FAPI-46 PET/CT not only can be clinically applied as a complement but also could become a necessary tool when standard-of-care imaging is inconclusive.
引用
- Rasinski P, Af Burén S, Holstensson M, et al. Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial. J Nucl Med. 2023. PMID: 37348917. doi:10.2967/jnumed.123.265481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。